Declining Incidence of Hepatitis C Virus Infection among People Who Inject Drugs in a Canadian Setting, 1996-2012
Open accessThe DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
BACKGROUND: People who inject drugs (PWID) are at high risk of hepatitis C virus (HCV) infection. Trends in HCV incidence and associated risk factors among PWID recruited between 1996 and 2012 in Vancouver, Canada were evaluated. METHODS: Data were derived from a long-term cohort of PWID in Vancouver. Trends in HCV incidence were evaluated. Factors associated with time to HCV infection were assessed using Cox proportional hazards regression. RESULTS: Among 2,589, 82% (n = 2,121) were HCV antibody-positive at enrollment. Among 364 HCV antibody-negative participants with recent (last 30 days) injecting at enrollment, 126 HCV seroconversions were observed [Overall HCV incidence density: 8.6 cases/100 person-years (py); 95% confidence interval (95% CI): 7.2, 10.1; HCV incidence density among those with injecting during follow-up: 11.5 cases/100 py; 95% CI 9.7, 13.6]. The overall HCV incidence density declined significantly from 25.0/100 py (95% CI: 20.2, 30.3) in 1996-99, as compared to 6.0/100 py (95% CI: 4.1, 8.5) in 2000-2005, and 3.1/100 py (95% CI: 2.0, 4.8) in 2006-2012. Among those with injecting during follow-up, the overall HCV incidence density declined significantly from 27.9/100 py (95% CI: 22.6, 33.6) in 1996-99, as compared to 7.5/100 py (95% CI: 5.1, 10.6) in 2000-2005, and 4.9/100 py (95% CI: 3.1, 7.4) in 2006-2012. Unstable housing, HIV infection, and injecting of cocaine, heroin and methamphetamine were independently associated with HCV seroconversion. CONCLUSIONS: HCV incidence has dramatically declined among PWID in this setting. However, improved public health strategies to prevent and treat HCV are urgently required to reduce HCV-associated morbidity and mortality.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




![Figure 5 Incidence density of HCV infection (per 100 person-years) among PWID in the VIDUS cohort by calendar year of enrolment and calendar year of observation. Each shaded area is a proportion relative to the largest incidence rate with 25.0 being 1 (full shading). The numeric values of the rates are used as the labels [95% CI]. Cells with N/A are blank.](https://figures.cochat.ai/paper-figures/4c3dfd0438e8465791fb9043ee1eccbc/declining-incidence-of-hepatitis-c-virus-infection-among-people-who-inject-drugs-figure-5.jpg)

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Despite dramatic reductions of HCV infection rates reported between 1996 and 2012 (Grebely et al. 2014), unstable housing continues to be an independent predictor associated with HCV infection (Grebely et al. 2014).”
From Clinical and functional characteristics of young adults living in single room occupancy housing: preliminary findings from a 10-year longitudinal study (2018) · cites this paper as Grebely et al. 2014
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nelson, P. K., Mathers, B. M., Cowie, B., Hagan, H., Des Jarlais, D., Horyniak, D., & Degenhardt, L. (2011) · The Lancet · doi:10.1016/s0140-6736(11)61097-0 · Cited by 1,267 · cited 1×
“Globally, it is estimated that 10 million PWID are HCV-infected worldwide, corresponding to a mid-point prevalence of 67% [1].”
BackgroundSharing of drug preparation equipment as a risk factor for hepatitis C
(2001) · American Journal of Public Health · doi:10.2105/ajph.91.1.42 · Cited by 500
Martin, N. K., Vickerman, P., Grebely, J., Hellard, M., Hutchinson, S. J., Lima, V. D., Foster, G. R., Dillon, J. F., Goldberg, D. J., Dore, G. J., et al. (2013) · Hepatology · doi:10.1002/hep.26431 · Cited by 488
Self-citationPage, K., Hahn, J. A., Evans, J., Shiboski, S., Lum, P., Delwart, E., Tobler, L., Andrews, W., Avanesyan, L., Cooper, S., et al. (2009) · The Journal of Infectious Diseases · doi:10.1086/605947 · Cited by 285
Miller, C. L., Johnston, C., Spittal, P. M., Li, K., LaLiberté, N., Montaner, J. S. G., & Schechter, M. T. (2002) · Hepatology · doi:10.1053/jhep.2002.35065 · Cited by 259
Self-citationProspective Evaluation of Community‐Acquired Acute‐Phase Hepatitis C Virus Infection
Cox, A. L., Netski, D. M., Mosbruger, T., Sherman, S. G., Strathdee, S., Ompad, D., Vlahov, D., Chien, D., Shyamala, V., Ray, S. C., et al. (2005) · Clinical Infectious Diseases · doi:10.1086/428578 · Cited by 231
Incidence and risk factors for hepatitis C seroconversion in injecting drug users in Australia
Maher, L., Jalaludin, B., Chant, K. G., Jayasuriya, R., Sladden, T., Kaldor, J. M., & Sargent, P. L. (2006) · Addiction · doi:10.1111/j.1360-0443.2006.01543.x · Cited by 227 · cited 1×
“Consistent with previous studies, unstable housing [17], injecting cocaine use [4,5,9,11,14,16,17] and injecting heroin use [9,11,17] were associated with HCV infection in this study.”
ResultPatrick, D. M., TYNDALL, M. W., Cornelisse, P., Li, K. K., Sherlock, C. H., Rekart, M. L., Strathdee, S. A., Currie, S. L., Schechter, M. T., & O’Shaughnessy, M. V. (2001) · Europe PMC (PubMed Central) · Cited by 203
Bruneau, J., Roy, É., Arruda, N., Zang, G., & Jutras‐Aswad, D. (2012) · Addiction · doi:10.1111/j.1360-0443.2012.03803.x · Cited by 171
Hepatitis C Virus Infection Among Injection Drug Users: Survival Analysis of Time to Seroconversion
Hagan, H., Thiede, H., & Des Jarlais, D. C. (2004) · Epidemiology · doi:10.1097/01.ede.0000135170.54913.9d · Cited by 170
Cited by
Platt, L., Minozzi, S., Reed, J., Vickerman, P., Hagan, H., French, C., Jordan, A., Degenhardt, L., Hope, V., Hutchinson, S., et al. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012021.pub2 · Cited by 305
Degenhardt, L., Charlson, F., Stanaway, J., Larney, S., Alexander, L. T., Hickman, M., Cowie, B., Hall, W. D., Strang, J., Whiteford, H., et al. (2016) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(16)30325-5 · Cited by 305
Mixed HCV infection and reinfection in people who inject drugs—impact on therapy
Cunningham, E. B., Applegate, T. L., Lloyd, A. R., Dore, G. J., & Grebely, J. (2015) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2015.36 · Cited by 105
Self-citationArtenie, A. A., Stone, J., Fraser, H., Stewart, D. E., Arum, C., Lim, A. G., McNaughton, A. L., Trickey, A., Ward, Z., Abramovitz, D. A., et al. (2023) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(23)00018-3 · Cited by 114
Self-citationBartlett, S., Yu, A., Chapinal, N., Rossi, C., Butt, Z. A., Wong, S., Darvishian, M., Gilbert, M., Wong, J., Binka, M., et al. (2019) · Liver International · doi:10.1111/liv.14227 · Cited by 104
Self-citationManagement of acute HCV infection in the era of direct-acting antiviral therapy
Martinello, M., Hajarizadeh, B., Grebely, J., Dore, G. J., & Matthews, G. V. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0026-5 · Cited by 108
Self-citationAcute hepatitis C virus infection: clinical update and remaining challenges
Liu, C., & Kao, J. (2023) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2022.0349 · Cited by 78
“Shared use of syringes and drug preparation equipment, more frequent injections, having numerous injecting partners, particular injection drug types, having HIV coinfection, and low socioeconomic state are the key risk factors of HCV transmission among PWID.(22,25,28,30)”
BackgroundInfluentialPhylogenetic clustering of hepatitis C virus among people who inject drugs in Vancouver, Canada
Jacka, B. P., Applegate, T. L., Krajden, M., Olmstead, A. D., Harrigan, R., Marshall, B. D. L., DeBeck, K., Milloy, M., Lamoury, F. M. J., Pybus, O. G., et al. (2014) · Hepatology · doi:10.1002/hep.27310 · Cited by 64
“These factors included: sex(1); education at baseline, defined as high school completion (yes versus no)(36); younger age(37); unstable housing status, defined as living in a single occupancy room in a hotel, a treatment or recovery house, jail, shelter or hostel, or having no fixed address in the last 6 months (yes v…”
BackgroundSelf-citationBrouard, C., Strat, Y. L., Larsen, C., Jauffret‐Roustide, M., Lot, F., & Pillonel, J. (2015) · PLoS ONE · doi:10.1371/journal.pone.0126920 · Cited by 55
Lima, V. D., Rozada, I., Grebely, J., Hull, M., Lourenço, L., Nosyk, B., Krajden, M., Yoshida, E. M., Wood, E., & Montaner, J. S. G. (2015) · PLoS ONE · doi:10.1371/journal.pone.0143836 · Cited by 46
“This can be asserted since in a recent paper focused on a large cohort of active PWID in BC followed since 1996, the Vancouver Injection Drug Users Study, we demonstrated that cocaine and heroin injection have continuously been the preferred injecting drugs in BC and highly predictive of HCV infection [37].”
BackgroundSelf-citationCunningham, E. B., Jacka, B., DeBeck, K., Applegate, T. L., Harrigan, P. R., Krajden, M., Marshall, B. D. L., Montaner, J., Lima, V. D., Olmstead, A. D., et al. (2015) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2015.04.005 · Cited by 35
“However, previous data have demonstrated that methamphetamine injection was independently associated with acquisition of HCV infection (Grebely et al., 2014; Drug Alcohol Depend.”
BackgroundInfluentialSelf-citationBarbic, S. P., Jones, A. A., Woodward, M., Piercy, M., Mathias, S., Vila-Rodriguez, F., Leonova, O., Smith, G. N., Buchanan, T., Vertinsky, A. T., et al. (2018) · Canadian Journal of Public Health · doi:10.17269/s41997-018-0087-9 · Cited by 26
“Despite dramatic reductions of HCV infection rates reported between 1996 and 2012 (Grebely et al. 2014), unstable housing continues to be an independent predictor associated with HCV infection (Grebely et al. 2014).”
BackgroundAitken, C. K., Agius, P. A., Higgs, P., Stoove, M. A., Bowden, D. S., & Dietze, P. (2016) · Epidemiology and Infection · doi:10.1017/s0950268816002892 · Cited by 30
Gutfraind, A., Boodram, B., Prachand, N., Hailegiorgis, A., Dahari, H., & Major, M. E. (2015) · PLoS ONE · doi:10.1371/journal.pone.0137993 · Cited by 30
Opioid agonist treatment and the process of injection drug use initiation
Mittal, M. L., Jain, S., Sun, S., DeBeck, K., Milloy, M., Hayashi, K., Hadland, S. E., & Werb, D. (2019) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2018.12.018 · Cited by 31
Self-citationLourenço, L., Kelly, M., Tarasuk, J., Stairs, K., Bryson, M., Popovic, N., & Aho, J. (2021) · Canada Communicable Disease Report · doi:10.14745/ccdr.v47i12a01 · Cited by 29
“Methamphetamine use has been associated with HCV transmission in Canadian studies (51,52) and linked to increased frequency of syringe sharing (53) and increased injection frequency (54).”
BackgroundHIV treatment as prevention among people who inject drugs – a re-evaluation of the evidence
Fraser, H., Mukandavire, C., Martin, N. K., Hickman, M., Cohen, M. S., Miller, W. C., & Vickerman, P. T. (2016) · International Journal of Epidemiology · doi:10.1093/ije/dyw180 · Cited by 28
“This is supported by data showing HCV incidence remained high till 2000 (> 15 per 100 person-years) despite there being high HCV sero-prevalence (82%),(10,11) and as Figure 1 shows, the decreases in HCV incidence followed HIV incidence trends suggesting that common factors affected both infections, which coincided wit…”
MethodResultInfluentialRoth, A. K., Denney, D. R., & LYNCH, S. G. (2015) · Journal of Clinical and Experimental Neuropsychology · doi:10.1080/13803395.2015.1037252 · Cited by 28
Iversen, J., Dore, G. J., Starr, M., Catlett, B., Cunningham, P., Geddes, L., & Maher, L. (2020) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2020.102837 · Cited by 24
Self-citationMolès, J., Vallo, R., Khuê, P. M., Hương, D. T., Oanh, K. T. H., Thoa, N. T., Giang, H. T., Thanh, N. T. T., Hai, V. V., Thi, T. A. B., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-63990-w · Cited by 23
Jacka, B. P., Applegate, T. L., Poon, A. F. Y., Raghwani, J., Harrigan, P. R., DeBeck, K., Milloy, M., Krajden, M., Olmstead, A. D., Joy, J. B., et al. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.02.031 · Cited by 22
“HCV incidence remains high, particularly among young PWID [2–5].”
BackgroundSelf-citationContextualizing Canada’s hepatitis C virus epidemic
Krajden, M., Cook, D. A., & Janjua, N. Z. (2018) · Canadian Liver Journal · doi:10.3138/canlivj.2018-0011 · Cited by 22
Self-citationEnhancing the detection and management of acute hepatitis C virus infection
Martinello, M., & Matthews, G. V. (2015) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2015.07.003 · Cited by 21
Valencia, J. A. S., Ryan, P., Álvaro‐Meca, A., Troya, J., Cuevas, G., Gutiérrez, J., & Moreno, S. (2018) · PLoS ONE · doi:10.1371/journal.pone.0204795 · Cited by 15
Roy, É., Arruda, N., Jutras‐Aswad, D., Berbiche, D., Perreault, M., Bertrand, K., Dufour, M., & Bruneau, J. (2017) · Addictive Behaviors · doi:10.1016/j.addbeh.2017.01.012 · Cited by 20
Goldenberg, S. M., Montaner, J., Braschel, M. C., Socias, M. E., Guillemi, S. A., & Shannon, K. (2016) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2016.12.019 · Cited by 22
“Although studies with PWID have estimated HCV incidence to be between 20 and 40/100 PY,(6) declining incidence has been demonstrated among PWID in Vancouver and other settings characterized by the scaleup of effective, community-based harm reduction programs.(20,21) To the authors’ knowledge, this is the first study t…”
BackgroundSelf-citationFalade-Nwulia, O. O., Hackman, J., Mehta, S. H., McCormick, S. D., Kirk, G. D., Sulkowski, M., Thomas, D. L., Latkin, C. A., Laeyendecker, O. B., & Ray, S. C. (2020) · BMC Infectious Diseases · doi:10.1186/s12879-020-05546-x · Cited by 14
Rozada, I., Coombs, D., & Lima, V. D. (2016) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2016.01.030 · Cited by 12
“For the 2006–2012 period, HCV incidence of new infections was 3.1 per 100 PY and 4.9 for individuals injecting during follow-up (Grebely et al., 2014b).”
InfluentialSelf-citationHøj, S. B., Minoyan, N., Artenie, A. A., Grebely, J., & Bruneau, J. (2018) · Canadian Liver Journal · doi:10.3138/canlivj.1.2.003 · Cited by 14
Self-citationArtenie, A. A., Roy, É., Zang, G., Jutras‐Aswad, D., Bamvita, J., Puzhko, S., Daniel, M., & Bruneau, J. (2015) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2015.04.013 · Cited by 11
Hepatitis C: clinical and biological features related to different forms of cocaine use
Schuch, S., Scherer, J. N., Kessler, F. H. P., Sordi, A. O., Pechansky, F., & DIEMEN, L. V. (2017) · Trends in Psychiatry and Psychotherapy · doi:10.1590/2237-6089-2016-0076 · Cited by 14
Poliquin, H., Bertrand, K., Flores-Aranda, J., & Roy, É. (2017) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2017.05.059 · Cited by 10
“For instance, in a cohort of PWID in British Columbia, crack use prevalence rose from 26% between 1996 and 1999 to 76% between 2006 and 2012 (Grebely et al., 2015).”
BackgroundFraser, H., Stone, J., Wisse, E., Sambu, V., Mfisi, P., Duran, I. J., Soriano, M. A., Walker, J. G., Makere, N., Luhmann, N., et al. (2021) · Journal of the International AIDS Society · doi:10.1002/jia2.25817 · Cited by 10
Jacka, B. P., Bray, B. C., Applegate, T. L., Marshall, B. D. L., Lima, V. D., Hayashi, K., DeBeck, K., Raghwani, J., Harrigan, P. R., Krajden, M., et al. (2017) · Journal of Viral Hepatitis · doi:10.1111/jvh.12758 · Cited by 8
“Within the VIDUS study, cocaine injecting was associated with a shorter time to HCV seroconversion (31).”
BackgroundSelf-citationCunningham, N. E., Lamb, J., Staller, A., Krajden, M., Hogg, R. S., Towle, A., Lima, V. D., & Salters, K. A. (2024) · Harm Reduction Journal · doi:10.1186/s12954-024-00991-2 · Cited by 11
“A prospective cohort of PWID in the largest urban area of BC found HCV incidence of 3.1/100 person-years (PY) between 2006 and 2012, despite widespread availability of free harm reduction supplies [7].”
BackgroundInfluentialSelf-citationHøj, S. B., Jacka, B. P., Minoyan, N., Bussière, P., & Bruneau, J. (2020) · Addiction · doi:10.1111/add.15192 · Cited by 9
Akhtar, F., & Rehman, S. (2018) · Cureus · doi:10.7759/cureus.2077 · Cited by 6
Antibody avidity-based approach to estimate population-level incidence of hepatitis C
Boon, D., Bruce, V. R., Patel, E. U., Quinn, J., Srikrishnan, A. K., Shanmugam, S., Iqbal, H. S., Balakrishnan, P., Sievers, M., Kirk, G. D., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.03.028 · Cited by 4
Cascade de prise en charge de l’hépatite C chronique en France métropolitaine
Brouard, C. (2019) · theses.fr (ABES) · doi:10.70675/398eca27z39b8z4a14za21dzcbb0a13598a6 · Cited by 4
Hepatitis C virus infection in patients receiving opiate substitution therapy in Sweden.
Jerkeman, A. (2014) · Lund University Publications (Lund University)
Machado, S. M. (2016) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.5.2016.tde-05012016-155346
Jacintho, C., & Correa, M. C. (2015)
Lourenço, L. C., Kelly, M., Tarasuk, J., Stairs, K., Bryson, M., Popovic, N., & Aho, J. (2021) · Relevé des maladies transmissibles au Canada · doi:10.14745/ccdr.v47i12a01f
“La consommation de méthamphétamine a été associée à la transmission du VHC dans des études canadiennes (51,52) et liée à une fréquence accrue du partage des seringues (53) et de l’injection (54).”
Meteliuk, A. (2016) · Scholars Archive - University at Albany (University at Albany, State University of New York) · doi:10.54014/aqhp-76p3
Tran, H. T., Duong, H. T., Khuê, P. M., Bình, N. T., Vallo, R., D’Ottavi, M., Giang, H. T., Hai, V. V., Khuat, O. T. H., Nham, T. T. T., et al. (2025) · Hepatology International · doi:10.1007/s12072-025-10856-w
“Only two studies conducted among drug users showed some evidence of association between HIV infection and HCV incidence, i.e., HR = 2.1 (95% CI 1.4–3.6) in China and HR = 1.8 (95% CI 1.0–3.1) in Canada [12, 13].”
InfluentialFalade-Nwulia, O. O., Hackman, J., Mehta, S. H., McCormick, S. D., Kirk, G. D., Sulkowski, M., Thomas, D. L., Latkin, C., Laeyendecker, O. B., & Ray, S. C. (2020) · Figshare · doi:10.6084/m9.figshare.13212542
Metadata
- Authors
- Grebely, J., Lima, V. D., Marshall, B. D. L., Milloy, M.-J., DeBeck, K., Montaner, J., Simo, A., Krajden, M., Dore, G. J., Kerr, T., & Wood, E.
- Affiliations
- UNSW Sydney (AU)
- University of British Columbia (CA)
- Brown University (US)
- Simon Fraser University (CA)
- BC Centre for Disease Control (CA)
- Corresponding author
- Grebely, Jason
- ORCID
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2014-06-04
- Volume
- 9
- Issue
- 6
- Pages
- e97726
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC4045728
- OpenAlex
- W2038073312
- Cited by
- 48
- References
- 37
- Citations by year
- 2025: 1 · 2024: 1 · 2023: 2 · 2021: 4 · 2020: 6 · 2019: 3 · 2018: 6 · 2017: 6 · 2016: 8 · 2015: 9 · 2014: 2
- FWCI
- 4.65
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- UNSWorks (UNSW Sydney) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Summit (Simon Fraser University) (submittedVersion, cc-by)
- UNSWorks (University of New South Wales, Sydney, Australia) (submittedVersion, cc-by)
- Funders
- Bristol-Myers Squibb
- World Health Organization
- Gilead Sciences
- UNICEF
- U.S. President’s Emergency Plan for AIDS Relief
- ViiV Healthcare
- Providence Health Care
- Australian Government
- Michael Smith Health Research BC
- Canada Research Chairs (Tier1)
- Simon Fraser University
- Ministry of Health, British Columbia (1DP1DA026182, R01DA011591)
- University of British Columbia
- International AIDS Society
- National Institutes of Health
- Canadian Institutes of Health Research (R01DA011591, RAA- 79918, HES- 115697, 129971_1, 125948_1, HHP- 67262)
- National Health and Medical Research Council
- National Institute on Drug Abuse (DP1DA026182, R03DA033851, R01DA011591)
- Topics
- Health Sciences › Medicine › Hepatology › Hepatitis C virus research
- Health Sciences › Medicine › Epidemiology › HIV, Drug Use, Sexual Risk
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Keywords
- hepatitis C virus, people who inject drugs, HCV seroconversion, intravenous drug use, cocaine use, heroin use, methamphetamine use, HIV coinfection, unstable housing, risk factors, Vancouver, harm reduction, needle exchange programs, HCV screening, HCV seroprevalence
- MeSH terms
- Adult, Canada, Female, Hepatitis C, Humans, Male, Surveys and Questionnaires, Risk Factors, Substance Abuse, Intravenous, Incidence
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.